Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Indibulin (D 24851) 是一种口服有效的微管蛋白合成抑制剂,具有抗有丝分裂和抗肿瘤活性,且神经毒性小。它降低了肌间神经张力,产生异常的纺锤体,激活有丝分裂检查点蛋白 Mad2 和 BubR1,并诱导有丝分裂停滞和细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 248 | 现货 | ||
2 mg | ¥ 355 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 928 | 现货 | ||
25 mg | ¥ 1,950 | 现货 | ||
50 mg | ¥ 3,160 | 现货 | ||
100 mg | ¥ 4,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | Indibulin (D 24851) is a synthetic small molecule with antimitotic and potential antineoplastic activities.Indibulin an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis. |
体外活性 | Indibulin, a synthetic inhibitor of tubulin assembly, has shown promising anticancer activity.?Using time-lapse confocal microscopy, indibulin dampens the dynamic instability of individual microtubules in live breast cancer cells.?Indibulin treatment also perturbed the localization of end-binding proteins at the growing microtubule ends in MCF-7 cells.?Indibulin reduced inter-kinetochoric tension, produced aberrant spindles, activated mitotic checkpoint proteins Mad2 and BubR1, and induced mitotic arrest in MCF-7 cells.?Indibulin-treated MCF-7 cells underwent apoptosis-mediated cell death.?Further, the combination of indibulin with an anticancer drug vinblastine was found to exert synergistic cytotoxic effects on MCF-7 cells.?Interestingly, indibulin displayed a stronger effect on the undifferentiated neuroblastoma (SH-SY5Y) cells than the differentiated neuronal cells.?Unlike indibulin, vinblastine and colchicine produced similar depolymerizing effects on microtubules in both differentiated and undifferentiated SH-SY5Y cells. |
别名 | 2-(1-(4-氯苄基)-1H-吲哚-3-基)-2-氧代-N-(吡啶-4-基)乙酰胺, ZIO 301, D 24851 |
分子量 | 389.83 |
分子式 | C22H16ClN3O2 |
CAS No. | 204205-90-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (128.26 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5652 mL | 12.8261 mL | 25.6522 mL | 64.1305 mL |
5 mM | 0.513 mL | 2.5652 mL | 5.1304 mL | 12.8261 mL | |
10 mM | 0.2565 mL | 1.2826 mL | 2.5652 mL | 6.4131 mL | |
20 mM | 0.1283 mL | 0.6413 mL | 1.2826 mL | 3.2065 mL | |
50 mM | 0.0513 mL | 0.2565 mL | 0.513 mL | 1.2826 mL | |
100 mM | 0.0257 mL | 0.1283 mL | 0.2565 mL | 0.6413 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Indibulin 204205-90-3 Apoptosis Cytoskeletal Signaling Microtubule Associated 2-(1-(4-氯苄基)-1H-吲哚-3-基)-2-氧代-N-(吡啶-4-基)乙酰胺 D24851 Inhibitor inhibit ZIO 301 D-24851 D 24851 ZIO-301 Microtubule/Tubulin ZIO301 inhibitor